Results 41 to 50 of about 68,946 (284)

An In-house Method for Molecular Monitoring of BCR-ABL

Turkish Journal of Hematology, 2012
OBJECTIVE: At present in Turkey, centers that are able to give reliable RQ-PCR BCR-ABL results are limited in number. We aimed to describe a cost-effective, in-house method for BCR-ABL quantification and to illustrate an example for RQ-PCR validation ...
Hakkı Ogun Sercan, Ilgın Öztürk, Ceyda Çalışkan, Melek Pehlivan, Zeynep Sercan   +4 more
doaj   +1 more source

The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.

Blood, 1997
The Philadelphia chromosome found in virtually all cases of chronic myeloid leukemia (CML) and in about one third of the cases of adult acute lymphoblastic leukemia is formed by a reciprocal translocation between chromosomes 9 and 22 that results in the ...
M. Deininger, J. Goldman, N. Lydon, J. Melo   +3 more
semanticscholar   +1 more source

Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib)

Molecular Cancer, 2012
Background Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemias (Ph-positive ALL) with clinically approved inhibitors of the Bcr/Abl tyrosine kinase frequently results in the emergence of a leukemic clone carrying the T315I ...
Fei Fei, Lim Min, Schmidhuber Sabine, Moll Jürgen, Groffen John, Heisterkamp Nora   +5 more
doaj   +1 more source

IMPENDING CARDIAC TAMPONADE AS THE INITIAL MANIFESTATION OF BCR-ABL-POSITIVE CML [PDF]

Chest, 2020
Gaballa, Salem, Hlaing, Kyaw, Moursy, Safa, Ahmed, Ameenjamal, Patel, Brijesh, Rallis, Austin, Dexter, David   +6 more
europepmc   +4 more sources

The c-Myc Oncoprotein Interacts with Bcr [PDF]

, 2003
Bcr is a multifunctional protein that is the fusion partner for Abl (p210 Bcr-Abl) in Philadelphia chromosome positive leukemias. We have identified c-Myc as a binding partner for Bcr in both yeast and mammalian cells.
Arlinghaus, Ralph B., Cheng, Li, Korus, Malgorzata, Kostenko, Elena, Mahon, Gwendolyn M., Sun, Tong, Wang, Yan, Whitehead, Ian P.   +7 more
core   +1 more source

Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide [PDF]

Blood, 1996
In chronic myeloid leukemia (CML) the classical 9;22 translocation results in a BCR-ABL fusion gene, which encodes chimeric BCR-ABL fusion 210 kD oncoproteins (p210BCR-ABL). The two main p210BCR-ABL fusion variants in CML, b2a2 and b3a2 are examples of well characterized antigens expressed by malignant cells.
GJ Bosch, AM Joosten, JH Kessler, Melief Cj, O. C. Leeksma   +4 more
openalex   +4 more sources

Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia [PDF]

Leukemia, 2010
Dasatinib is a potent dual Abl/Src inhibitor approved for treatment of Philadelphia chromosome-positive (Ph-positive) leukemias. At a once-daily dose and a relatively short half-life of 3-5 h, tyrosine kinase inhibition is not sustained. However, transient inhibition of K562 leukemia cells with a high-dose pulse of dasatinib or long-term treatment with
Yong-Mi Kim, Yong-Mi Kim, John Groffen, Sonia Stoddart, Markus Müschen, Markus Müschen, Fei Fei, Nora Heisterkamp   +7 more
openaire   +4 more sources

Uptake of synthetic low density lipoprotein by leukemic stem cells — a potential stem cell targeted drug delivery strategy [PDF]

, 2010
Chronic Myeloid Leukemia (CML) stem/progenitor cells, which over-express Bcr-Abl, respond to imatinib by a reversible block in proliferation without significant apoptosis.
Alison M. Michie, Baillie, Bellodi, Bhatia, Bocchia, Brown, Claire Crossan, Collins, Copland, Davies, Deckelbaum, Dirks, Firestone, Gal, Gavin W. Halbert, Ghalaut, Graham, Halbert, Hamilton, Hamilton, Hatziieremia, Hayavi, Hayavi, Heather G. Jørgensen, Ho, Hochhaus, Holyoake, Hughes, Jordanides, Jorgensen, Jorgensen, Kramer, Linda Scobie, Moira A. Elliott, Nikanjam, Nikanjam, Owens, Peixun Zhou, Rousselot, Sophia Hatziieremia, Stingl, Tatidis, Tessa L. Holyoake, Vitols, Weisberg, White, White, WilsonRawls   +47 more
core   +1 more source

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.

Journal of Clinical Oncology, 2006
PURPOSE A novel therapeutic approach is urgently needed for BCR-ABL-positive acute lymphoblastic leukemia (ALL). In this study, we assessed the efficacy and feasibility of chemotherapy combined with imatinib.
M. Yanada, J. Takeuchi, I. Sugiura, H. Akiyama, N. Usui, F. Yagasaki, Tohru Kobayashi, Y. Ueda, M. Takeuchi, S. Miyawaki, A. Maruta, N. Emi, Y. Miyazaki, S. Ohtake, I. Jinnai, K. Matsuo, T. Naoe, R. Ohno   +17 more
semanticscholar   +1 more source

Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib

Blood Cancer Journal, 2015
Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL -positive chronic myelogenous leukemia treated with ruxolitinib and ...
A. Zhou, E. Knoche, E. Engle, Daniel A. C. Fisher, S. Oh   +4 more
semanticscholar   +1 more source